Star Lake Bioscience Co (600866) Fair Value & Analysis

Healthcare · CN · Market cap 7.4B CNY

Below-average quality, screening 155% undervalued on our models.

What matters now

• The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain.
• The price is below even our cautious bear case (¥8.01). The market is more pessimistic than our downside scenario.
• A fairly wide model range (¥8.01 to ¥14.58) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 8, 2026.

How to read this chart

60‑month range ¥3.53 – ¥8.49 · fair‑value band ¥8.01 – ¥14.58 · the ¥4.43 price screens below the ¥11.29 fair value. Dashed = 300-day average. As of Aug 8, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Star Lake Bioscience Co (600866) currently trades at ¥4.43, while our model-based Fair Value estimate is ¥11.29, implying the stock looks roughly 154.9% undervalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Star Lake Bioscience Co generated revenue of 15.6B CNY at a net margin of 2.9%. Revenue declined 7.4% year over year. It earns a return on equity of 5.3%. Net debt stands at 3.1B CNY. Fundamentals as of Aug 8, 2026

Our scenario range runs from ¥8.01 (bear case) to ¥14.58 (bull case); at ¥4.43, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 48% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 155%, 600866 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (¥15.61) versus Asset-Based (¥3.31). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally.

Full company description

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally. The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an intermediate for food and pharmaceutical raw material; adefovir dipivoxil tablets used to reduce the activity of HBV DNA polymerase and anti-virus by destroying Hepatitis B virus DNA; and L-threonine that is used in premixtures, and pig and poultry feed. It also provides disodium 5'-ribonucleotide to cure chronic hepatitis, muscular atrophy, and eye diseases; disodium 5-inosinate to cure leukopenia, thrombocytopenia, and chronic and acute hepatitis; and inosine, which is used for the treatment of chronic and acute hepatitis, heart disease, leukopenia or thrombocytopenia, central choroidoretinitis, etc. In addition, the company offers disodium 5'-guanylate for canned and salted meat, ham, etc. Further, it provides ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, L-threonine, L-lysine, etc. Star Lake Bioscience Co., Inc.Zhaoqing Guangdong was founded in 1964 and is based in Zhaoqing, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Star Lake Bioscience Co reported revenue of ¥15.9B in FY2025 versus ¥4.1B in FY2021, a compound +40.6%/yr. Reported net income was ¥979M in FY2025, compounding +59.3%/yr from FY2021.

Watch 600866: get an alert when its fair value changes →

Peer Group

Biotechnology · 603 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 8, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.